DAL‑1/4.1B contributes to epithelial‑mesenchymal transition via regulation of transforming growth factor‑β in lung cancer cell lines

Yu,Feng; Yang,Hua; Zhang,Zhanmin; Wang,Zhijun; Xiong,Jianping

doi:10.3892/mmr.2015.4217

DAL‑1/4.1B contributes to epithelial‑mesenchymal transition via regulation of transforming growth factor‑β in lung cancer cell lines

Authors:
- Feng Yu
- Hua Yang
- Zhanmin Zhang
- Zhijun Wang
- Jianping Xiong
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China
Published online on: August 12, 2015 https://doi.org/10.3892/mmr.2015.4217
Pages: 6072-6078

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effects of the tumor suppressor gene differentially expressed in adenocarcinoma of the lung 1 (DAL‑1)/4.1B on early‑stage adenocarcinoma of the lung. The role of DAL‑1/4.1B in the epithelial‑mesenchymal transition (EMT), which is implicated in cancer metastasis, was examined using DAL‑1 knockdown and overexpression, followed by polymerase chain reaction and western blot analysis of EMT markers, as well as cell counting and cell migration/invasion assays. The results showed that DAL‑1/4.1B has a role in transforming growth factor (TGF)‑β‑induced EMT in non‑small cell lung cancer cells. Silencing of DAL‑1/4.1B with inhibitory RNAs altered the expression of numerous EMT markers, including E‑cadherin and β‑catenin, whereas overexpression of DAL‑1/4.1B had the opposite effect. In addition, DAL‑1/4.1B expression was induced following TGF‑β treatment at the protein and mRNA level. DAL‑1/4.1B deficiency impaired TGF‑β‑induced EMT and increased cell migration and invasion. These results suggested that DAL‑1/4.1B contributed to the EMT and may be important for tumor metastasis in lung cancer. Together with the results of a previous study by our group, the present study suggested that DAL‑1/4.1B acts as a tumor suppressor in the early transformation process in lung cancer, while in later stages, it functions as an oncogene affecting the biological features of human lung carcinoma cells. The results of the present study provided evidence for the feasibility of utilizing DAL‑1/4.1B as a target for lung cancer gene therapy.

View Figures

View References

1	Sculier JP, Berghmans T and Meert AP: Small cell lung cancer: What are the treatment results in routine management? Lung Cancer. 84:101–102. 2014. View Article : Google Scholar : PubMed/NCBI
2	Tran YK, Bogler O, Gorse KM, Wieland I, Green MR and Newsham IF: A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer. Cancer Res. 59:35–43. 1999.PubMed/NCBI
3	Takakuwa Y: Protein 4.1, a multifunctional protein of the erythrocyte membrane skeleton: Structure and functions in erythrocytes and nonerythroid cells. Int J Hematol. 72:298–309. 2000.
4	Steenbergen RD, Kramer D, Braakhuis BJ, Stern PL, Verheijen RH, Meijer CJ and Snijders PJ: TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst. 96:294–305. 2004. View Article : Google Scholar : PubMed/NCBI
5	Lu B, Di W, Wang H, Ma H, Li J and Zhang Q: Tumor suppressor TSLC1 is implicated in cell proliferation, invasion and apoptosis in laryngeal squamous cell carcinoma by regulating Akt signaling pathway. Tumour Biol. 33:2007–2017. 2012. View Article : Google Scholar : PubMed/NCBI
6	Heller G, Geradts J, Ziegler B, Newsham I, Filipits M, Markis-Ritzinger EM, Kandioler D, Berger W, Stiglbauer W, Depisch D, et al: Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat. 103:283–291. 2007. View Article : Google Scholar : PubMed/NCBI
7	Ito T, Shimada Y, Hashimoto Y, Kaganoi J, Kan T, Watanabe G, Murakami Y and Imamura M: Involvement of TSLC1 in progression of esophageal squamous cell carcinoma. Cancer Res. 63:6320–6326. 2003.PubMed/NCBI
8	Mao X, Seidlitz E, Truant R, Hitt M and Ghosh HP: Re-expression of TSLC1 in a non-small-cell lung cancer cell line induces apoptosis and inhibits tumor growth. Oncogene. 23:5632–5642. 2004. View Article : Google Scholar : PubMed/NCBI
9	Kikuchi S, Yamada D, Fukami T, Masuda M, Sakurai-Yageta M, Williams YN, Maruyama T, Asamura H, Matsuno Y, Onizuka M and Murakami Y: Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer. Clin Cancer Res. 11:2954–2961. 2005. View Article : Google Scholar : PubMed/NCBI
10	Goto A, Niki T, Chi-Pin L, Matsubara D, Murakami Y, Funata N and Fukayama M: Loss of TSLC1 expression in lung adenocarcinoma: Relationships with histological subtypes, sex and prognostic significance. Cancer Sci. 96:480–486. 2005. View Article : Google Scholar : PubMed/NCBI
11	Gutmann DH, Hirbe AC, Huang ZY and Haipek CA: The protein 4.1 tumor suppressor, DAL-1, impairs cell motility, but regulates proliferation in a cell-type-specific fashion. Neurobiol Dis. 8:266–278. 2001. View Article : Google Scholar : PubMed/NCBI
12	Robb VA, Gerber MA, Hart-Mahon EK and Gutmann DH: Membrane localization of the U2 domain of Protein 4.1B is necessary and sufficient for meningioma growth suppression. Oncogene. 24:1946–1957. 2005. View Article : Google Scholar : PubMed/NCBI
13	Franco-Chuaire ML, Magda Carolina SC and Chuaire-Noack L: Epithelial-mesenchymal transition (EMT): Principles and clinical impact in cancer therapy. Invest Clin. 54:186–205. 2013.PubMed/NCBI
14	Nieto MA: Epithelial-Mesenchymal Transitions in development and disease: Old views and new perspectives. Int J Dev Biol. 53:1541–1547. 2009. View Article : Google Scholar : PubMed/NCBI
15	Elliott RL and Blobe GC: Role of transforming growth factor Beta in human cancer. J Clin Oncol. 23:2078–2093. 2005. View Article : Google Scholar : PubMed/NCBI
16	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
17	Goel A, Chhabra R, Ahmad S, Prasad AK, Parmar VS, Ghosh B and Saini N: DAMTC regulates cytoskeletal reorganization and cell motility in human lung adenocarcinoma cell line: An integrated proteomics and transcriptomics approach. Cell Death Dis. 3:e4022012. View Article : Google Scholar : PubMed/NCBI
18	Tran Y, Benbatoul K, Gorse K, Rempel S, Futreal A, Green M and Newsham I: Novel regions of allelic deletion on chromosome 18p in tumors of the lung, brain and breast. Oncogene. 17:3499–505. 1998. View Article : Google Scholar
19	Yageta M, Kuramochi M, Masuda M, Fukami T, Fukuhara H, Maruyama T, Shibuya M and Murakami Y: Direct association of TSLC1 and DAL-1, two distinct tumor suppressor proteins in lung cancer. Cancer Res. 62:5129–5133. 2002.PubMed/NCBI
20	Zhang Y, Xu R, Li G, Xie X, Long J and Wang H: Loss of expression of the differentially expressed in adenocarcinoma of the lung (DAL-1) protein is associated with metastasis of non-small cell lung carcinoma cells. Tumour Biol. 33:1915–1925. 2012. View Article : Google Scholar : PubMed/NCBI
21	Bernkopf DB and Williams ED: Potential role of EPB41L3 (protein 4.1B/Dal-1) as a target for treatment of advanced prostate cancer. Expert Opin Ther Targets. 12:845–853. 2008. View Article : Google Scholar : PubMed/NCBI
22	Cavanna T, Pokorna E, Vesely P, Gray C and Zicha D: Evidence for protein 4.1B acting as a metastasis suppressor. J Cell Sci. 120:606–616. 2007. View Article : Google Scholar : PubMed/NCBI
23	Ohno N, Terada N, Murata S, Yamakawa H, Newsham IF, Katoh R, Ohara O and Ohno S: Immunolocalization of protein 4.1B/DAL-1 during neoplastic transformation of mouse and human intestinal epithelium. Histochem Cell Biol. 122:579–586. 2004. View Article : Google Scholar : PubMed/NCBI
24	Christofori G and Semb H: The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci. 24:73–76. 1999. View Article : Google Scholar : PubMed/NCBI
25	Liu Q, Mao H, Nie J, Chen W, Yang Q, Dong X and Yu X: Transforming growth factor {beta}1 induces epithelial-mesenchymal transition by activating the JNK-Smad3 pathway in rat peritoneal mesothelial cells. Perit Dial Int. 28(Suppl 3): S88–S95. 2008.PubMed/NCBI
26	Xu XL, Ling ZQ, Chen SZ, Li B, Ji WH and Mao WM: The impact of E-cadherin expression on the prognosis of esophageal cancer: A meta-analysis. Dis Esophagus. 27:79–86. 2014. View Article : Google Scholar
27	Nakaya Y and Sheng G: EMT in developmental morphogenesis. Cancer Lett. 341:9–15. 2013. View Article : Google Scholar : PubMed/NCBI
28	Saito A: EMT and EndMT: Regulated in similar ways? J Biochem. 153:493–495. 2013. View Article : Google Scholar : PubMed/NCBI
29	Willis BC and Borok Z: TGF-beta-induced EMT: Mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol. 293:L525–L534. 2007. View Article : Google Scholar : PubMed/NCBI
30	Duangkumpha K, Techasen A, Loilome W, Namwat N, Thanan R, Khuntikeo N and Yongvanit P: BMP-7 blocks the effects of TGF-beta-induced EMT in cholangiocarcinoma. Tumour Biol. 35:9667–9676. 2014. View Article : Google Scholar : PubMed/NCBI